We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparison of Resources Utilization (RU) and Costs in Drug-Naive Type 2 Diabetes (T2D) Patients (Pts) Treated with Rosiglitazone (RSG)/ Metformin (MET) as Fixed-Dose Combination (FDC) vs. Sulfonylurea (SU) plus Metformin (MET) as Combination Therapy (CT).
- Authors
Mei Sheng Duh; Gosselin, Antoine; Beaulieu, Nicolas; Arana, Mateo; Arondekar, Bhakti
- Abstract
This study compares RU and costs for drug-naive pts treated with RSGMETFDC versus SUMET separate pills as first-line CT using real-world claims data. Based on medical, pharmacy (Rx), and disability claims data from 10/2001 to 12/2000, T2D diagnosed patients newly initiated on oral anti-diabetic agents (OAD) (no OAD in previous 6 months), ± 18 years, and with ± 60 days of uninterrupted treatment were analyzed. Frequency of inpatient (inpt) and outpatient (outpt) visits and average direct (inpt, outpt, and Rx) and indirect (workloss) costs were compared between the RSGMETFDC and SUMET groups. 1,507 RSGMETFDC and 1,255 SUMET pts met the inclusion criteria. RSGMETFDC pts were slightly younger (58.6 vs. 59.5 years, p<0.045) with less comorbidities (Charlson comorbidity index 0.71 vs. 0.82, p=0.024) at baseline. Univariate results showing a trend toward lower RU and costs in the RSGMETFDC group were confirmed by multivariate analyses controlling for age, gender, comorbidities, and other covariates. During treatment, the RSGMETFDC group incurred significantly less frequent inpt visits (0.36 less visits per pt per year (PPPY), p<0.001), outpt visits (3.32 less visits PPPY, p<0.001), and number of hospital days (1.08 less days PPPY, p<0.001) than SUMET group. Total direct cost was significantly lower in the RSGMETFDC group ($162 reduction per pt per month (PPPM), p= 0.003) than the SUMET group, including significantly lower inpt and outpt cost ($143 reduction PPPM, p= 0.005) which offset the higher Rx cost ($12 increase PPPM, p=0.080). After accounting for the indirect workloss cost, the total direct and indirect cost was significantly lower in the RM group ($172 reduction PPPM, p=0.002). This observational study of 2,762 pts initiated on first-line RSGMETFDC vs. SUMET CT shows that RSGMETFDC pts incur significantly lower RU, and total direct and indirect cost than SUMET pts, despite higher drug cost.
- Subjects
TYPE 2 diabetes treatment; PEOPLE with diabetes; HYPOGLYCEMIC agents; MEDICAL care costs; MEDICAL care use; DRUG utilization
- Publication
Diabetes, 2007, Vol 56, pA558
- ISSN
0012-1797
- Publication type
Article